{"filing":{"accession_number":"0001104659-26-091619","cik":"0001425205","ticker":"IOVA","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tm2622322d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_8k.htm"},"events":[{"id":25402,"run_id":23054,"accession_number":"0001104659-26-091619","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Q2 2026 financial results for Iovance Biotherapeutics. The filing explicitly states \"issued a press release announcing its financial results for the second quarter ended June 30, 2026\" under Item 2.02. The press release reports record revenue of ~$99M (up 66% YoY), gross margin of 56%, and includes business achievements and corporate updates. This is a standard quarterly earnings disclosure material to investors.","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26223,"accession_number":"0001104659-26-091619","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Iovance Biotherapeutics. The filing explicitly states \"issued a press release announcing its financial results for the second quarter ended June 30, 2026\" under Item 2.02. The press release reports record revenue of ~$99M (up 66% YoY), gross margin of 56%, and includes business achievements and corporate updates. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:01.329976+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26223,"accession_number":"0001104659-26-091619","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Iovance Biotherapeutics. The filing explicitly states \"issued a press release announcing its financial results for the second quarter ended June 30, 2026\" under Item 2.02. The press release reports record revenue of ~$99M (up 66% YoY), gross margin of 56%, and includes business achievements and corporate updates. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:39:01.329976+00:00","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","filing_date":"2026-08-06"}]}